MMP Inhibitor

Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrochloride is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrochloride significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrochloride not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrochloride exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrochloride may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrochloride can be used in research related to hypertension and atherosclerosis.

Kukoamine B (Standard) is the analytical standard of Kukoamine B. This product is intended for research and analytical applications. Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with K_d values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis.

PI3K/AKT-IN-7 is a PI3K/Akt signaling pathway inhibitor with selective antiproliferative activity against hepatocellular carcinoma cells. PI3K/AKT-IN-7 downregulates the phosphorylation of PI3K and Akt and binds to NCF2 (K_d = 1.40 μM). PI3K/AKT-IN-7 induces apoptosis, S-phase cell cycle arrest, loss of mitochondrial membrane potential, and ROS accumulation, while inhibiting proliferation, migration, invasion, and DNA synthesis. PI3K/AKT-IN-7 inhibits tumor growth in a Hep3B xenograft BALB/c mouse model and reduces the expression of Ki67, PCNA, and MMP9. PI3K/AKT-IN-7 can be used for research on hepatocellular carcinoma.

MMP-2/9-IN-2 (Compound 6k) is a MMP-2 and MMP-9 inhibitor, with IC₅₀ values of 29.27 and 24.87 μM respectively. MMP-2/9-IN-2 exhibits good selective toxicity against multiple human hepatoma cell lines. MMP-2/9-IN-2 induces cell cycle arrest and apoptosis, significantly inhibits cell migration and invasion. MMP-2/9-IN-2 inhibits the phosphorylation of the STAT3 signaling pathway. MMP-2/9-IN-2 shows strong anti-tumor activity in a nude mouse xenograft model of HepG2 liver cancer cells.

ABT-518 is a matrix metalloproteinase inhibitor with anti-tumor activity. ABT-518 has potent inhibitory effects on gelatinase A and gelatinase B, which can inhibit tumor growth and metastasis.

TAT-QFNP12 is a peptide that blocks the NDRG2-PPM1A binding and reduces Smad2/3 phosphorylation, decreases astrocytic MMP-9 production and BBB disruption after subarachnoid hemorrhage (SAH).

MG-3C is a potent matrix metalloproteinase 9 (MMP-9) inhibitor. MG-3C can selectively kill non-small-cell lung cancer (NSCLC) cells harboring the EGFR T790M mutation. MG-3C blocks the EGFR/STAT3 signaling pathway, inducing G2/M phase arrest, growth inhibition, and apoptosis of cancer cells. MG-3C is promising for research of lung cancer.

Glucocorticoid receptor-IN-2 (Compound WX019) is a selective glucocorticoid receptor (GR) modulator with anti-inflammatory effect. Glucocorticoid receptor-IN-2 exhibits very good transcriptional repressive activity with an IC₅₀ of 0.171 nM against hMMP1, and comparable transcriptional activation activity with an EC₅₀ of 0.94 nM against MMTV.

Sucrosofate potassium (Standard) (Sucrose octasulfate potassium) (Standard)) is the analytical standard of Sucrosofate potassium (HY-141436). This product is intended for research and analytical applications. Sucrosofate potassium (Sucrose octasulfate potassium) is a wound healing promoter. Sucrosofate potassium inhibits MMP, promotes angiogenesis and improves microcirculation. Sucrosofate potassium causes mild skin irritation. Sucrosofate potassium can be used to prepare p (MMA-co-AM)/PVA@PSO hydrogels. Sucrosofate potassium is applicable to research related to diabetic wounds.

Mmp10 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mmp10 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Coriolus Versicolor Extract is a biological response modifier (BRM) with anti-cancer and anti-migratory properties. Coriolus Versicolor Extract can also inhibit the expression of tumorigenic factors associated with inflammation and can be used in cancer research.

Tubulin polymerization-IN-82 is a tubulin inhibitor. Tubulin polymerization-IN-82 inhibits cell migration and invasion, and triggers cell apoptosis through the mitochondria and ER stress mediated pathway. Tubulin polymerization-IN-82 exhibits antitumor activity against drug resistance cancer cells, and inhibits tumor growth, can be used for liver cancer research.

MMP8 Human Pre-designed siRNA Set A contains three designed siRNAs for MMP8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Berkeleyamide B is a dual matrix metalloproteinase-3 (MMP-3) and caspase-1 inhibitor. Berkeleyamide B is promising for research of cancers and inflammatory disease (e.g., rheumatoid arthritis).

anti-TNBC agent-9 (Compound 3as) is an anti-cancer agent for triple-negative breast cancer (TNBC). anti-TNBC agent-9 exhibits significant inhibitory activity against MDA-MB-453 cells with an IC₅₀ value of 8.5 μM. anti-TNBC agent-9 inhibits tumor cell migration by upregulating E-cadherin and downregulating N-cadherin, matrix metalloproteinase 2 (MMP2), and MMP9. anti-TNBC agent-9 induces apoptosis by increasing the expression of the pro-apoptotic protein BAX and decreasing the expression of the anti-apoptotic protein BCL-2, thereby inhibiting tumor cell proliferation.

OART (Oxaliplatin-artesunate) is a ferroptosis inducer. OART significantly inhibits tumor cell proliferation. OART induces cytoplasmic and mitochondrial LPO to promote tumor ferroptosis, via destroying glutathione-mediated ferroptosis defense system and enhancing iron-dependent Fenton reaction. OART enhances tumor immunogenicity, transforming tumor environment from immunosuppressive to immunosensitive. OART has strong tumor regression in tumor-bearing mouse models. OART can be used for cancer immunotherapy research.

Anticancer agent 306 is a spiro tetramic acid derivative and a inhibitor of MMP1, MMP7 and PLK1. Anticancer agent 306 exerts antiproliferative activity against H1299, RKO and MCF-7 cells with IC₅₀ values of 19.25 μM, 3.29 μM and 102.36 μM, respectively. Anticancer agent 306 can up-regulate p21 protein and down-regulate CCND1 and CCNB1 proteins to induce cell cycle arrest, regulate the expression of Bcl-2 and Bax to induce cell apoptosis. Anticancer agent 306 can down-regulate MMP1 and MMP7 proteins to inhibit tumor invasion and metastasis. Anticancer agent 306 can be used for the research of lung cancer, colorectal cancer, breast cancer.

20(R)-Ginsenoside Rh2 (Standard) is the analytical standard of 20(R)-Ginsenoside Rh2. This product is intended for research and analytical applications. 20(R)-Ginsenoside Rh2 is an orally active protopanaxadiol-type saponin with multiple biological activities. 20(R)-Ginsenoside Rh2 exerts a significant inhibitory effect on non-small cell lung cancer and liver cancer by inducing cell cycle arrest and promoting apoptosis. 20(R)-Ginsenoside Rh2 exerts anti-γ-herpesvirus effects by inhibiting viral DNA replication. 20(R)-Ginsenoside Rh2 inhibits inflammatory mediators by reducing the levels of NO, PGE2, and ROS; it can delay skin photoaging by reducing ROS and inhibiting MMP-9/2 activity. 20(R)-Ginsenoside Rh2 accelerates the recovery after muscle injury by activating the Akt1/PKB signaling pathway. 20(R)-Ginsenoside Rh2 can inhibit osteoclast formation and exert an anti-osteoporosis effect.

Chamazulene, a natural compound, is an antioxidant-type inhibitor of leukotriene B4 formation.

Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrobromide is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrobromide significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrobromide not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrobromide exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrobromide may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrobromide can be used in research related to hypertension and atherosclerosis.